Obviously, the main signaling pathways engaged in the targets of FSH for tumor treatment were Pathways in cancer, Prostate cancer, PI3K-Akt signaling pathway, EGFR tyrosine kinase inhibitor resistance, and Proteoglycans in cancer. Here, BRD2 is linked to prostate carcinoma.